All In Biotech

Drug Trial Radar · NCT01847924

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects : a Pilot Double Blind, Placebo-controlled Randomized Trial on Efficacy and Safety (NEURITES) Study

Last checked: Nov 19, 2026Latest source record: Jul 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Mar 2013

Primary completion

Apr 2018

Study completion Apr 2018

Sponsor

Lead sponsor
National University Hospital, SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who have suffered from stroke may develop problems with thinking. Moreover, such patients have a high risk of becoming demented, more dependent or dying. Therefore, further studies are urgently needed to find effective and safe treatments. Neuroaid is a Traditional Chinese Medicine which has been shown to stimulate growth of brain cells and connections in animals. Neuroaid may improve blood flow in the brain and functional recovery after stroke in patients. Neuroaid-II is a simplified formula with only the main 9 herbal ingredients of the original formula and no animal ingredients. The NEURoaid II (MLC 901) assessment in cognitively Impaired not demented subjects: a pilot double blind, placebo-controlled randomized Trial on Efficacy and Safety (NEURITES) Study is a 24-week, early phase trial of Neuroaid-II in patients who have thinking problems after stroke. The study aims to investigate the effectiveness of the study drug in improving cognitive performance. The safety of the study drug will be closely monitored using adverse events, laboratory tests and vital signs. The trial is important as it aims to set new standards for the scientific evaluation of Asian Traditional Medicine for integration into standard medicine practice. It may potentially establish a novel therapeutic approach for improving cognition after stroke.

Conditions

  • Cognitive Impairment

Interventions

  • MLC901Drug

    24 weeks intervention with orally MLC901. 2 capsules 3 times a day

  • PlaceboDrug

    24 weeks intervention with orally placebo. 2 capsules 3 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparative change on executive functionTime frame: Baseline to 24th week(24 week)

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Santo Tomas Hospital

    Manila, National Capital Region, Philippines

  • National University Hospital

    Singapore, Singapore

  • Singapore General Hospital

    Singapore, Singapore

  • National Neuroscience Institute

    Singapore, Singapore

  • National Geriatric Hospital

    Hanoi, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.